Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) in Complete Molecular Response (CMR) within 3 Months of Therapy with Tyrosine Kinase Inhibitors (TKIs)

被引：2

作者：

Sasaki, Koji ^{[1
]}

Kantarjian, Hagop M. ^{[1
]}

Samra, Bachar ^{[1
]}

Short, Nicholas J. ^{[2
]}

Khoury, Joseph D. ^{[3
]}

Kanagal-Shamanna, Rashmi ^{[3
]}

Konopleva, Marina Y. ^{[1
]}

Jain, Nitin ^{[1
]}

DiNardo, Courtney D. ^{[1
]}

Khouri, Rita ^{[1
]}

Garcia-Manero, Guillermo ^{[1
]}

Kadia, Tapan M. ^{[1
]}

Wierda, William G. ^{[1
]}

Tippett, Nicole ^{[1
]}

Garris, Rebecca ^{[1
]}

Jeanis, Victoria ^{[1
]}

Daver, Naval G. ^{[1
]}

Thompson, Philip A. ^{[1
]}

Yilmaz, Musa ^{[1
]}

Cortes, Jorge E. ^{[1
]}

O'Brien, Susan M. ^{[4
]}

Ravandi, Farhad ^{[1
]}

Jabbour, Elias ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA

[4] Univ Calif Irvine Hlth, Div Hematol Oncol, Dept Med, Chao Family Comprehens Canc Ctr, Orange, CA USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-128619

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[21] Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors (TKIs) in patients (pts) with Philadelphia chromosome-positive (Ph plus ) leukemia: Phase 1/2 study update.
Gambacorti-Passerini, Carlo
Lipton, Jeffrey Howard
Hochhaus, Andreas
Kota, Vamsi K.
Baccarani, Michele
Durrant, Simon
Assouline, Sarit E.
Kim, Dong-Wook
Bruemmendorf, Tim H.
Leip, Eric
An, Fiona
Aguiar, Jean
Cortes, Jorge E.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[22] Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive (PH plus ) Chronic Myeloid Leukemia (CML) or PH plus Acute Lymphoblastic Leukemia (ALL): a Pharmacokinetic Study
Hijiya, Nobuko
Zwaan, C. Michel
Rizzari, Carmelo
Foa, Roberto
Abbink, Floor
Lancaster, Donna
Landman-Parker, Judith
Millot, Frederic
Moppett, John
Nelken, Brigitte
Ducassou, Stephane
Putti, Maria Caterina
Tian, Xianbin
Sinclair, Karen
Santanastasio, Helene
Buchbinder, Aby
Kearns, Pamela
PEDIATRIC BLOOD & CANCER, 2017, 64 : S34 - S34
[23] The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI)
Sasaki, Koji
Ribera, Josep-Maria
Figueroa, Mary
Ravandi, Farhad
Short, Nicholas J.
Garcia-Manero, Guillermo
Daver, Naval G.
Kadia, Tapan M.
Konopleva, Marina Y.
Jain, Nitin
Issa, Ghayas C.
Estrov, Zeev E.
Garris, Rebecca
Khouri, Rita
Nasnas, Patrice
DiNardo, Courtney D.
Naqvi, Kiran
Kornblau, Steven M.
Montalban-Bravo, Guillermo
Pemmaraju, Naveen
Cortes, Jorge E.
O'Brien, Susan M.
Chandra, Joya
Kantarjian, Hagop M.
Jabbour, Elias
BLOOD, 2019, 134
[24] Assessment of Molecular Response to Tyrosine Kinase Inhibitors in Tunisian Patients With Ph plus Acute Lymphoblastic Leukemia
Frikha, Rim
El Aoud, Amina
Kamoun, Hassen
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S237 - S237
[25] Screening ABL1 kinase domain mutations in patients with de novo Philadelphia chromosome-positive (Ph plus ) acute lymphoblastic leukemia (ALL)
Li, He
Zhang, Wanhua
Yi, Dongni
Ye, Yuanxin
Xiao, Xueqiu
LEUKEMIA & LYMPHOMA, 2017, 58 (04) : 1005 - 1007
[26] Impact of Tyrosine Kinase Inhibitors on Minimal Residual Disease and Outcome in Childhood Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Jeha, Sima
Coustan-Smith, Elaine
Pei, Deqing
Sandlund, John T.
Rubnitz, Jeffrey E.
Howard, Scott C.
Inaba, Hiroto
Bhojwani, Deepa
Metzger, Monika L.
Cheng, Cheng
Choi, John K.
Jacobsen, Jeffrey
Shurtleff, Sheila A.
Raimondi, Susana
Ribeiro, Raul C.
Pui, Ching-Hon
Campana, Dario
CANCER, 2014, 120 (10) : 1514 - 1519
[27] Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience
Papayannidis, Cristina
Lacobucci, Ilaria
Soverini, Simona
Colarossi, Sabrina
Gnani, Alessandra
Lonetti, Annalisa
Ferrari, Anna
Testoni, Nicoletta
Amabile, Marilina
Ottaviani, Emanuela
Abbenante, Maria Chiara
Curti, Antonio
Paolini, Stefania
Lama, Barbara
Clissa, Cristina
Parisi, Sarah
Guadagnuolo, Viviana
Baccarani, Michele
Martinelli, Giovanni
CANCER RESEARCH, 2010, 70
[28] EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE
Papayannidis, C.
Iacobucci, I.
Soverini, S.
Paolini, S.
Clissa, C.
Parisi, S.
Abbenante, M. C.
Colarossi, S.
Gnani, A.
Lonetti, A.
Ferrari, A.
Testoni, N.
Amabile, M.
Ottaviani, E.
Curti, A.
Guadagnuolo, V.
Baccarani, M.
Martinelli, G.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 257 - 257
[29] The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Zhang, Yuanfeng
Feng, Sizhou
LEUKEMIA RESEARCH, 2021, 109
[30] Smoking Confers Poor Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI)
Jabbour, Elias J.
Sasaki, Koji
Ravandi, Farhad
Short, Nicholas J.
Garcia-Manero, Guillermo
Daver, Naval G.
Kadia, Tapan M.
Konopleva, Marina Y.
Jain, Nitin
Issa, Ghayas C.
Estrov, Zeev E.
Garris, Rebecca E.
Khouri, Maria
Nasnas, Patrice
Pemmaraju, Naveen
Cortes, Jorge E.
O'Brien, Susan M.
Kantarjian, Hagop M.
BLOOD, 2018, 132

← 1 2 3 4 5 →